InvestorsHub Logo
Followers 95
Posts 11594
Boards Moderated 0
Alias Born 12/27/2011

Re: Willhoitemusic post# 16973

Wednesday, 05/17/2017 2:31:54 PM

Wednesday, May 17, 2017 2:31:54 PM

Post# of 37495
Omni Health was previously a privately owned pharmacy in Hialeah, FL that started in business over 40 years ago. Around 2007, it was purchased by LX Retail Group (another privately held firm). Last June, VitaCig, Inc.(OTC:VTCQ), which had been spun off from mCig (OTC:MCIG), did a reverse merger in which it's VitaCig product line was sold back to mCig in return for roughly 37% of its 47% ownership shares and LX Retail sold 100% of Malecon Pharmacy to VitaCig, Inc in return for controlling interest in VTCQ. The result was that VTCQ became Malecon Pharmacy with LX Retail Group as the primary controlling shareholder. LX Retail then renamed the company to Omni Health and changed the stock symbol to OMHE.

Malecon Pharmacy Website

For the next several months, Omni was preoccupied with completing the merger and auditing and submitting its financials to the SEC. That process is now complete and we can now see that the new company has roughly $6 million/year in revenue and has generated over $1 million in earnings/profit. Their pro-forma statement from the 3FQ17 10-Q (financials thru 1/31/17) shows the results of Malecon's operations when separated from the old VitaCig financials and merger...

Omni 3FQ17 10-Q Financials



The merger was a quick way for LX Retail to transform Malecon into a public company. It's obvious that the company didn't go public just to operate a pharmacy. Shareholders have been anxiously waiting to find out exactly what Omni's plans are for future growth. We recently uncovered their website which is still under construction. It shows that they are planning to announce six new divisions...

Omni Health Website



They've previously indicated that they are working on developing an anti-aging cream. They've also announced that they have opened a research facility and started a Medical Advisory Board. Indications are that they will be developing pharmaceuticals and will be cultivating and conducting research on cannabinoids. Shareholders are now anxiously waiting for the next shoe to drop when they reveal their business and growth plan. Their fiscal year ended on 4/30/17 and their next financials won't be due until July 30 and can be delayed until 8/15/17 before they are considered delinquent. We should hear something by then but probably sooner (could be any day).

Les